Latest Articles
What We’re Reading: Misleading ACA Ads; Codifying Roe v Wade; Ovarian Cancer Risk in Women With Endometriosis - AJMC.com Managed Markets Network
What We’re Reading: Misleading ACA Ads; Codifying Roe v Wade; Ovarian Cancer Risk in Women With Endometriosis AJMC.com Managed Markets Network
Published: July 18, 2024, 7 a.m.
Black patients may be missed on common cancer screening, study suggests - Livescience.com
Black patients may be missed on common cancer screening, study suggests Livescience.com
Published: July 16, 2024, 7 a.m.
If you’ve ever been dismissed by a doctor, read this book - inews
If you’ve ever been dismissed by a doctor, read this book inews
Published: July 13, 2024, 7 a.m.
Ultrasound Screening Often Misses Endometrial Cancer in Black Females - Healthline
Ultrasound Screening Often Misses Endometrial Cancer in Black Females Healthline
Published: July 9, 2024, 7 a.m.
Bindi Irwin on Her Health: Star Says Endometriosis Symptoms Were "Dismissed" - Distractify
Bindi Irwin on Her Health: Star Says Endometriosis Symptoms Were "Dismissed" Distractify
Published: July 7, 2024, 7 a.m.
Christie's pain was dismissed for decades, then she developed 'terminal' endometriosis - 9News
Christie's pain was dismissed for decades, then she developed 'terminal' endometriosis 9News
Published: July 2, 2024, 7 a.m.
Isha Ambani on Conceiving Twins Through IVF: 5 Misconceptions You Should Stop Believing Now - India.com
Isha Ambani on Conceiving Twins Through IVF: 5 Misconceptions You Should Stop Believing Now India.com
Published: June 29, 2024, 7 a.m.
The Targeted Pulse: Endometrial Cancer Scores Multiple FDA Approvals, T-DXd Shows Promise in Breast Cancer, and More - Targeted Oncology
The Targeted Pulse: Endometrial Cancer Scores Multiple FDA Approvals, T-DXd Shows Promise in Breast Cancer, and More Targeted Oncology
Published: June 23, 2024, 7 a.m.
Lenvatinib/Pembrolizumab Misses OS End Points, But Still Shows Activity, in Advanced Endometrial Cancer - OncLive
Lenvatinib/Pembrolizumab Misses OS End Points, But Still Shows Activity, in Advanced Endometrial Cancer OncLive
Published: June 21, 2024, 7 a.m.
ROCSAN Study Step I Misses 16-Week ORR End Point in Endometrial or Ovarian Carcinosarcoma - OncLive
ROCSAN Study Step I Misses 16-Week ORR End Point in Endometrial or Ovarian Carcinosarcoma OncLive
Published: June 20, 2024, 7 a.m.
Link copied to clipboard!